Zum Hauptinhalt springen
Hochschulbibliothek der Hochschule Düsseldorf

Programmed cell death disrupts inflammatory tumor microenvironment (TME) and promotes glioblastoma evolution.

Liang, T ; Gu, L ; et al.
In: Cell communication and signaling : CCS, Jg. 22 (2024-06-18), Heft 1, S. 333
Online academicJournal
Zugriff:
Full Text Finder (Volltext)

Glioblastoma (GBM) is the most common malignant brain tumor and has a dismal prognosis even under the current first-line treatment, with a 5-year survival rate less than 7%. Therefore, it is important to understand the mechanism of treatment resistance and develop new anti-tumor strategies. Induction of programmed cell death (PCD) has become a promising anti-tumor strategy, but its effectiveness in treating GBM remains controversial. On the one hand, PCD triggers tumor cell death and then release mediators to draw in immune cells, creating a pro-inflammatory tumor microenvironment (TME). One the other hand, mounting evidence suggests that PCD and inflammatory TME will force tumor cells to evolve under survival stress, leading to tumor recurrence. The purpose of this review is to summarize the role of PCD and inflammatory TME in the tumor evolution of GBM and promising methods to overcome tumor evolution.

(© 2024. The Author(s).)

Titel:
Programmed cell death disrupts inflammatory tumor microenvironment (TME) and promotes glioblastoma evolution.
Autor/in / Beteiligte Person: Liang, T ; Gu, L ; Kang, X ; Li, J ; Song, Y ; Wang, Y ; Ma, W
Link:
Zeitschrift: Cell communication and signaling : CCS, Jg. 22 (2024-06-18), Heft 1, S. 333
Veröffentlichung: [London] : BioMed Central, c2003-, 2024
Medientyp: academicJournal
ISSN: 1478-811X (electronic)
DOI: 10.1186/s12964-024-01602-0
Schlagwort:
  • Humans
  • Apoptosis
  • Animals
  • Glioblastoma pathology
  • Glioblastoma genetics
  • Tumor Microenvironment
  • Inflammation pathology
  • Brain Neoplasms pathology
  • Brain Neoplasms genetics
Sonstiges:
  • Nachgewiesen in: MEDLINE
  • Sprachen: English
  • Publication Type: Journal Article; Review
  • Language: English
  • [Cell Commun Signal] 2024 Jun 18; Vol. 22 (1), pp. 333. <i>Date of Electronic Publication: </i>2024 Jun 18.
  • MeSH Terms: Glioblastoma* / pathology ; Glioblastoma* / genetics ; Tumor Microenvironment* ; Inflammation* / pathology ; Brain Neoplasms* / pathology ; Brain Neoplasms* / genetics ; Humans ; Apoptosis ; Animals
  • References: Front Immunol. 2022 Mar 30;13:847345. (PMID: 35432318) ; Mol Syst Biol. 2021 Jun;17(6):e9522. (PMID: 34101353) ; Clin Cancer Res. 2019 Mar 15;25(6):1709-1717. (PMID: 30413527) ; Cancers (Basel). 2020 Mar 01;12(3):. (PMID: 32121554) ; Am J Cancer Res. 2021 Apr 15;11(4):1069-1086. (PMID: 33948346) ; Mol Cancer. 2004 Dec 08;3(1):36. (PMID: 15588281) ; ACS Chem Biol. 2020 Feb 21;15(2):469-484. (PMID: 31899616) ; Front Oncol. 2022 Jun 27;12:917634. (PMID: 35832539) ; Nat Commun. 2021 Nov 26;12(1):6938. (PMID: 34836966) ; Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022 Sep;14(5):e1826. (PMID: 35735205) ; Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):343-9. (PMID: 23462419) ; Exp Cell Res. 2023 Mar 1;424(1):113474. (PMID: 36702193) ; J Leukoc Biol. 2007 Nov;82(5):1322-31. (PMID: 17711975) ; Chest. 2018 Dec;154(6):1416-1423. (PMID: 30189190) ; Nat Rev Immunol. 2020 Mar;20(3):143-157. (PMID: 31690840) ; Neuro Oncol. 2012 Nov;14(11):1379-92. (PMID: 22965162) ; Neuro Oncol. 2023 Oct 4;25(12 Suppl 2):iv1-iv99. (PMID: 37793125) ; Oxid Med Cell Longev. 2022 May 11;2022:9925919. (PMID: 35602105) ; J Clin Oncol. 2019 Feb 1;37(4):318-327. (PMID: 30557521) ; Science. 2021 Sep 17;373(6561):1327-1335. (PMID: 34529489) ; Cancer Cell. 2021 Jun 14;39(6):845-865.e7. (PMID: 34019806) ; Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1570-80. (PMID: 16580506) ; Diagn Interv Imaging. 2017 Sep;98(9):651-659. (PMID: 28579522) ; Semin Radiat Oncol. 2022 Apr;32(2):168-171. (PMID: 35307119) ; Cancer Med. 2023 Feb;12(4):5071-5087. (PMID: 36161280) ; Front Immunol. 2018 Dec 21;9:2924. (PMID: 30619286) ; Am J Cancer Res. 2021 Sep 15;11(9):4582-4594. (PMID: 34659907) ; J Surg Res. 2019 Aug;240:115-123. (PMID: 30927618) ; Brief Bioinform. 2021 Sep 2;22(5):. (PMID: 33839757) ; Autophagy. 2013 Feb 1;9(2):246-8. (PMID: 23108329) ; Nat Commun. 2017 May 10;8:15207. (PMID: 28488695) ; Front Cell Dev Biol. 2020 Jul 09;8:538. (PMID: 32733879) ; Front Med. 2021 Aug;15(4):551-561. (PMID: 33893983) ; Int J Mol Sci. 2019 Jun 29;20(13):. (PMID: 31261963) ; J Nucl Med. 2021 Jul 1;62(7):949-955. (PMID: 33246980) ; Cancer Immunol Immunother. 2020 Jul;69(7):1191-1204. (PMID: 32144446) ; Radiat Oncol. 2017 Dec 29;12(1):206. (PMID: 29284495) ; Int J Mol Sci. 2021 Jan 28;22(3):. (PMID: 33525678) ; JAMA Oncol. 2020 Jul 1;6(7):1003-1010. (PMID: 32437507) ; Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):721-6. (PMID: 14967426) ; J Inflamm Res. 2022 Jan 04;15:17-32. (PMID: 35018108) ; Dis Markers. 2022 Apr 1;2022:4534080. (PMID: 35401877) ; Cell Mol Immunol. 2021 May;18(5):1106-1121. (PMID: 33785842) ; Curr Neurol Neurosci Rep. 2020 May 22;20(7):19. (PMID: 32445058) ; Acta Neuropathol. 2022 Mar;143(3):291-310. (PMID: 35039931) ; Nat Rev Immunol. 2020 May;20(5):274-275. (PMID: 32203327) ; Acta Pharmacol Sin. 2022 Nov;43(11):2977-2992. (PMID: 35581292) ; Nat Med. 2019 Mar;25(3):470-476. (PMID: 30742120) ; Br J Cancer. 2023 Nov;129(11):1829-1840. (PMID: 37777579) ; Front Oncol. 2020 Jun 23;10:897. (PMID: 32656078) ; Cancer Cell. 2015 Sep 14;28(3):318-28. (PMID: 26373279) ; Br J Cancer. 2016 Mar 1;114(5):485-96. (PMID: 26889975) ; Front Cell Dev Biol. 2022 Apr 25;10:862493. (PMID: 35547808) ; Neuro Oncol. 2023 Jan 5;25(1):123-134. (PMID: 35419607) ; Nat Commun. 2020 Oct 27;11(1):5424. (PMID: 33110073) ; N Engl J Med. 2005 Mar 10;352(10):997-1003. (PMID: 15758010) ; Immunity. 2010 Jan 29;32(1):129-40. (PMID: 20079667) ; Cell. 2022 Jun 9;185(12):2184-2199.e16. (PMID: 35649412) ; Cancer Cell. 2023 Feb 13;41(2):304-322.e7. (PMID: 36638784) ; Neuro Oncol. 2022 Nov 2;24(11):1935-1949. (PMID: 35511454) ; Trends Mol Med. 2021 Sep;27(9):856-867. (PMID: 34312075) ; Carcinogenesis. 2018 May 3;39(5):689-699. (PMID: 29538621) ; Cell. 1996 Jun 14;85(6):781-4. (PMID: 8681372) ; Neuro Oncol. 2010 Jun;12(6):559-69. (PMID: 20156803) ; Hum Vaccin Immunother. 2021 Feb 1;17(2):546-553. (PMID: 32643507) ; Neuro Oncol. 2022 Jul 1;24(7):1113-1125. (PMID: 35148413) ; Nat Rev Mol Cell Biol. 2021 Apr;22(4):266-282. (PMID: 33495651) ; Lancet. 2021 Sep 11;398(10304):1002-1014. (PMID: 34509219) ; Lancet Oncol. 2009 May;10(5):459-66. (PMID: 19269895) ; Br J Radiol. 2012 Sep;85(1017):e770-81. (PMID: 22919020) ; Cell Death Dis. 2022 Oct 8;13(10):861. (PMID: 36209275) ; J Neurooncol. 2021 Feb;151(3):429-442. (PMID: 33611709) ; Neuro Oncol. 2018 May 18;20(6):743-752. (PMID: 29040782) ; Nat Rev Microbiol. 2009 Feb;7(2):99-109. (PMID: 19148178) ; Pharmacol Ther. 2018 Apr;184:13-41. (PMID: 29080702) ; Cell Biosci. 2021 Mar 31;11(1):63. (PMID: 33789726) ; Nat Commun. 2020 Oct 5;11(1):4997. (PMID: 33020472) ; Cancer Metastasis Rev. 2017 Jun;36(2):375-393. (PMID: 28707199) ; Genes Dev. 2007 Dec 15;21(24):3342-55. (PMID: 18079180) ; Cell. 2012 May 11;149(4):780-94. (PMID: 22579283) ; Acta Neuropathol. 2022 Dec;144(6):1127-1142. (PMID: 36178522) ; Adv Drug Deliv Rev. 2022 Jun;185:114311. (PMID: 35489652) ; Front Oncol. 2019 Apr 02;9:215. (PMID: 31001479) ; Neuro Oncol. 2020 Aug 17;22(8):1062-1064. (PMID: 32479631) ; Oncogene. 2013 Feb 7;32(6):699-712. (PMID: 22525272) ; Nat Rev Clin Oncol. 2021 May;18(5):280-296. (PMID: 33514910) ; Cell Commun Signal. 2023 May 19;21(1):115. (PMID: 37208730) ; Nat Commun. 2017 Feb 15;8:. (PMID: 28198370) ; JAMA. 2015 Dec 15;314(23):2535-43. (PMID: 26670971) ; Cell Death Differ. 2004 Apr;11(4):448-57. (PMID: 14713959) ; Neuro Oncol. 2021 Apr 12;23(4):677-686. (PMID: 33173935) ; J Exp Med. 2017 Jun 5;214(6):1711-1724. (PMID: 28442553) ; Lancet. 2001 Feb 17;357(9255):539-45. (PMID: 11229684) ; Oncotarget. 2017 Jun 27;8(26):43237-43247. (PMID: 28591733) ; Front Neurol. 2019 Jan 31;10:42. (PMID: 30766509) ; Int J Mol Med. 2015 Nov;36(5):1244-52. (PMID: 26329365) ; Protein Cell. 2014 Jan;5(1):12-20. (PMID: 24474192) ; Cell Death Dis. 2018 Aug 6;9(8):841. (PMID: 30082680) ; Yonsei Med J. 2021 Sep;62(9):843-849. (PMID: 34427071) ; Br J Cancer. 2021 Feb;124(4):697-709. (PMID: 33144698) ; Chin Med J (Engl). 2009 Jun 5;122(11):1255-9. (PMID: 19567133) ; Nat Rev Cancer. 2014 Mar;14(3):199-208. (PMID: 24561446) ; Autophagy. 2015;11(7):1099-113. (PMID: 25701485) ; Cell Mol Immunol. 2022 Sep;19(9):971-992. (PMID: 35970871) ; Cell Metab. 2021 May 4;33(5):1001-1012.e5. (PMID: 33691090) ; Sci Transl Med. 2017 Jul 19;9(399):. (PMID: 28724573) ; Proc Natl Acad Sci U S A. 2019 Jan 22;116(4):1361-1369. (PMID: 30545915) ; Radiat Oncol. 2022 Jan 25;17(1):17. (PMID: 35073960) ; J Natl Compr Canc Netw. 2023 Jan;21(1):12-20. (PMID: 36634606) ; Front Oncol. 2019 Oct 14;9:1017. (PMID: 31681570) ; Cancer Lett. 2020 Apr 1;474:151-157. (PMID: 31991153) ; Cell. 2021 Apr 29;184(9):2454-2470.e26. (PMID: 33857425) ; Neuro Oncol. 2018 Oct 9;20(11):1429-1438. (PMID: 29509936) ; Clin Cancer Res. 2017 Oct 15;23(20):6279-6291. (PMID: 28754819) ; Front Pharmacol. 2022 Jun 14;13:911760. (PMID: 35774612) ; Autophagy. 2020 Nov;16(11):2069-2083. (PMID: 31920150) ; J Clin Invest. 2022 Apr 15;132(8):. (PMID: 35199647) ; Cell Death Differ. 2007 Mar;14(3):548-58. (PMID: 16946731) ; Nature. 2020 Mar;579(7799):421-426. (PMID: 32188939) ; Semin Immunol. 2014 Feb;26(1):38-47. (PMID: 24602448) ; Nat Commun. 2019 Sep 26;10(1):4375. (PMID: 31558756) ; Neurooncol Adv. 2022 Apr 06;4(1):vdac040. (PMID: 35611270) ; Cell Prolif. 2023 Mar;56(3):e13376. (PMID: 36681858) ; IEEE Rev Biomed Eng. 2018;11:195-207. (PMID: 29993870) ; Cancers (Basel). 2020 Mar 27;12(4):. (PMID: 32230726)
  • Grant Information: 2022-PUMCH-A-019 National High Level Hospital Clinical Research Funding
  • Contributed Indexing: Keywords: GBM; Inflammatory TME; PCD; Treatment; Tumor evolution
  • Entry Date(s): Date Created: 20240618 Date Completed: 20240619 Latest Revision: 20240624
  • Update Code: 20240625
  • PubMed Central ID: PMC11184850

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

oder
oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

oder
oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

xs 0 - 576
sm 576 - 768
md 768 - 992
lg 992 - 1200
xl 1200 - 1366
xxl 1366 -